IL312533A - Novel auristatin analogs and immunoconjugates thereof - Google Patents
Novel auristatin analogs and immunoconjugates thereofInfo
- Publication number
- IL312533A IL312533A IL312533A IL31253324A IL312533A IL 312533 A IL312533 A IL 312533A IL 312533 A IL312533 A IL 312533A IL 31253324 A IL31253324 A IL 31253324A IL 312533 A IL312533 A IL 312533A
- Authority
- IL
- Israel
- Prior art keywords
- int
- compound
- immunoconjugate
- ono
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275177P | 2021-11-03 | 2021-11-03 | |
| US202163295476P | 2021-12-30 | 2021-12-30 | |
| PCT/US2022/048735 WO2023081230A1 (en) | 2021-11-03 | 2022-11-02 | Novel auristatin analogs and immunoconjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312533A true IL312533A (en) | 2024-07-01 |
Family
ID=86241915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312533A IL312533A (en) | 2021-11-03 | 2022-11-02 | Novel auristatin analogs and immunoconjugates thereof |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4426714A4 (https=) |
| JP (1) | JP2024540402A (https=) |
| KR (1) | KR20240110584A (https=) |
| AU (1) | AU2022380491A1 (https=) |
| CA (1) | CA3236944A1 (https=) |
| IL (1) | IL312533A (https=) |
| MX (1) | MX2024005342A (https=) |
| TW (1) | TW202334176A (https=) |
| WO (1) | WO2023081230A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067221A1 (zh) * | 2023-09-26 | 2025-04-03 | 上海齐鲁制药研究中心有限公司 | 奥瑞他汀衍生物及其抗体药物偶联物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US20130190248A1 (en) * | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
| US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| WO2015017552A1 (en) * | 2013-08-01 | 2015-02-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
| CA3205824A1 (en) * | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
-
2022
- 2022-11-02 MX MX2024005342A patent/MX2024005342A/es unknown
- 2022-11-02 JP JP2024527084A patent/JP2024540402A/ja active Pending
- 2022-11-02 IL IL312533A patent/IL312533A/en unknown
- 2022-11-02 WO PCT/US2022/048735 patent/WO2023081230A1/en not_active Ceased
- 2022-11-02 KR KR1020247017701A patent/KR20240110584A/ko active Pending
- 2022-11-02 AU AU2022380491A patent/AU2022380491A1/en active Pending
- 2022-11-02 CA CA3236944A patent/CA3236944A1/en active Pending
- 2022-11-02 EP EP22890732.5A patent/EP4426714A4/en active Pending
- 2022-11-03 TW TW111142076A patent/TW202334176A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236944A1 (en) | 2023-05-11 |
| EP4426714A1 (en) | 2024-09-11 |
| AU2022380491A1 (en) | 2024-05-30 |
| TW202334176A (zh) | 2023-09-01 |
| MX2024005342A (es) | 2024-09-27 |
| KR20240110584A (ko) | 2024-07-15 |
| WO2023081230A1 (en) | 2023-05-11 |
| EP4426714A4 (en) | 2025-10-08 |
| JP2024540402A (ja) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020263231B2 (en) | Camptothecin derivatives | |
| JP6581630B2 (ja) | 新規ベンゾジアゼピン誘導体 | |
| JP2024038168A (ja) | 生物活性分子コンジュゲート、その調製法及び使用 | |
| CN106459055B (zh) | 双功能细胞毒类药剂 | |
| ES2867749T3 (es) | Conectores y su aplicación con respecto a los CAF | |
| CA3027178A1 (en) | Anti-egfr antibody drug conjugates | |
| TWI712605B (zh) | 含有cti藥效基團之雙功能性細胞毒性劑 | |
| WO2024059236A1 (en) | Novel camptothecin analogs and immunoconjugates thereof | |
| JP2025518554A (ja) | リガンド薬物複合体及びその使用 | |
| IL312533A (en) | Novel auristatin analogs and immunoconjugates thereof | |
| AU2022422015A1 (en) | Novel auristatin analogs and immunoconjugates thereof | |
| CN121574085A (zh) | 缀合物及其用途 | |
| EP4471005A1 (en) | Conjugate and use thereof | |
| CN118541378A (zh) | 新型澳瑞他汀类似物及其免疫偶联物 | |
| HK40117241A (zh) | 新型澳瑞他汀类似物及其免疫偶联物 | |
| HK40115429A (zh) | 新型澳瑞他汀类似物及其免疫偶联物 | |
| CA3137125C (en) | Camptothecin derivatives | |
| WO2025176733A1 (en) | Antibody-drug conjugates involving small molecule atr/chk1 inhibitors | |
| WO2024127332A1 (en) | Cytotoxic compounds | |
| WO2024127333A1 (en) | Cytotoxic compounds | |
| CN121358743A (zh) | 用于治疗或预防癌症的喜树碱衍生物及其抗体药物偶联物 | |
| HK40069519A (en) | Camptothecin derivatives | |
| HK1233252A1 (en) | Bifunctional cytotoxic agents |